BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11848685)

  • 1. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein.
    Niwa K; Kazama K; Younkin SG; Carlson GA; Iadecola C
    Neurobiol Dis; 2002 Feb; 9(1):61-8. PubMed ID: 11848685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exogenous A beta1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice.
    Niwa K; Carlson GA; Iadecola C
    J Cereb Blood Flow Metab; 2000 Dec; 20(12):1659-68. PubMed ID: 11129782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
    van Groen T; Kiliaan AJ; Kadish I
    Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched Typical Western Diet (TWD).
    Hooijmans CR; Rutters F; Dederen PJ; Gambarota G; Veltien A; van Groen T; Broersen LM; Lütjohann D; Heerschap A; Tanila H; Kiliaan AJ
    Neurobiol Dis; 2007 Oct; 28(1):16-29. PubMed ID: 17720508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central cholinergic functions in human amyloid precursor protein knock-in/presenilin-1 transgenic mice.
    Hartmann J; Erb C; Ebert U; Baumann KH; Popp A; König G; Klein J
    Neuroscience; 2004; 125(4):1009-17. PubMed ID: 15120860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence and co-localization of amyloid beta-protein and apolipoprotein E in perivascular drainage channels of wild-type and APP-transgenic mice.
    Thal DR; Larionov S; Abramowski D; Wiederhold KH; Van Dooren T; Yamaguchi H; Haass C; Van Leuven F; Staufenbiel M; Capetillo-Zarate E
    Neurobiol Aging; 2007 Aug; 28(8):1221-30. PubMed ID: 16815595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.
    Kandimalla KK; Wengenack TM; Curran GL; Gilles EJ; Poduslo JF
    J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice.
    Tong XK; Nicolakakis N; Fernandes P; Ongali B; Brouillette J; Quirion R; Hamel E
    Neurobiol Dis; 2009 Sep; 35(3):406-14. PubMed ID: 19524673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prion protein (PrPc) promotes beta-amyloid plaque formation.
    Schwarze-Eicker K; Keyvani K; Görtz N; Westaway D; Sachser N; Paulus W
    Neurobiol Aging; 2005; 26(8):1177-82. PubMed ID: 15917101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A transgenic rat model of Alzheimer's disease with extracellular Abeta deposition.
    Flood DG; Lin YG; Lang DM; Trusko SP; Hirsch JD; Savage MJ; Scott RW; Howland DS
    Neurobiol Aging; 2009 Jul; 30(7):1078-90. PubMed ID: 18053619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced cerebral blood flow but elevated cerebral glucose metabolic rate in erythropoietin overexpressing transgenic mice with excessive erythrocytosis.
    Frietsch T; Maurer MH; Vogel J; Gassmann M; Kuschinsky W; Waschke KF
    J Cereb Blood Flow Metab; 2007 Mar; 27(3):469-76. PubMed ID: 16804549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contrasting in vivo effects of two peptide-based amyloid-beta protein aggregation inhibitors in a transgenic mouse model of amyloid deposition.
    Li Q; Gordon M; Etienne MA; Hammer RP; Morgan D
    Cell Transplant; 2008; 17(4):397-408. PubMed ID: 18522242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced brain tissue perfusion in TGF-beta 1 transgenic mice showing Alzheimer's disease-like cerebrovascular abnormalities.
    Gaertner RF; Wyss-Coray T; Von Euw D; Lesné S; Vivien D; Lacombe P
    Neurobiol Dis; 2005; 19(1-2):38-46. PubMed ID: 15837559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
    Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
    J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease.
    Boissonneault V; Filali M; Lessard M; Relton J; Wong G; Rivest S
    Brain; 2009 Apr; 132(Pt 4):1078-92. PubMed ID: 19151372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease.
    Mohmmad Abdul H; Sultana R; Keller JN; St Clair DK; Markesbery WR; Butterfield DA
    J Neurochem; 2006 Mar; 96(5):1322-35. PubMed ID: 16478525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation.
    Kandimalla KK; Curran GL; Holasek SS; Gilles EJ; Wengenack TM; Poduslo JF
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1370-8. PubMed ID: 15743932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholinergic neuropathology in a mouse model of Alzheimer's disease.
    German DC; Yazdani U; Speciale SG; Pasbakhsh P; Games D; Liang CL
    J Comp Neurol; 2003 Aug; 462(4):371-81. PubMed ID: 12811807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.
    Evin G; Zhu A; Holsinger RM; Masters CL; Li QX
    J Neurosci Res; 2003 Nov; 74(3):386-92. PubMed ID: 14598315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.